FDA Finds No Risk of Death Linked to Paclitaxel-Coated Balloons and Stents
The FDA has reversed its opinion on paclitaxel-coated balloons and stents, saying they no longer believe the implants increase the risk of death for patients.
The FDA has reversed its opinion on paclitaxel-coated balloons and stents, saying they no longer believe the implants increase the risk of death for patients.
A new study appears to identify factors which increase the risk of peripheral neuropathy linked to the use of some cancer drugs.
The FDA is calling for clinical trials to continue, with some precautions, into potential mortality risks linked to balloons and stents coated with paclitaxel.
French officials are conducting a safety review of Taxotere following at least five deaths linked to the drug since last summer.